Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease


A single, 2 g/kg dose of immune globulin (IG), denoted 2 g-intravenous (IV)IG, has become a standard regimen for treating Kawasaki disease (KD) because of its highly preventive effect on coronary arterial lesions (CAL). However, IG is obtained from blood specimens, a drawback to many patients, and is also very expensive. This randomized prospective study reported here was carried out with the aim of developing a treatment regimen that would reduce the total dose of IG. The study tested two protocols (A: 2 g-IVIG; B: 1 g-IVIG) that included the strategy of administering additional IVIG to IVIG-resistant patients based on the criteria we described previously. In protocol A, an additional 2 g-IVIG was administered only once; in protocol B, the first additional IVIG was 1 g-IVIG and the second was 2 g-IVIG. One hundred and nine patients who were admitted before the seventh day of illness and had no CAL at the time of admission were enrolled in the study (protocol A: 54 patients; B: 55 patients). In the protocol A group, 7.4% (4/54) of the patients received 4 g/kg IG. In protocol B, 41.8% (23/55) were treated only with 1 g/kg IG, and 10.9% (6/55) received 4 g/kg IG. No significant differences were observed between the patients of the two subgroups receiving 4 g/kg IG in each protocol group. Discriminate analysis also suggested that 52.4% of the patients in the protocol A group could be treated only with 1 g/kg IG. On the other hand, no significant difference was observed in the incidence of aneurysms between patients in the protocol A group (1/54) and those in the protocol B group (4/55). Our protocol based on 1 g-IVIG, including additional IVIG, was assessed to be an effective treatment and to provide a considerably useful means to reduce the total dose of IG.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2



Coronary arterial lesions


Immune globulin


Intravenous immune globulin


Kawasaki disease


left coronary artery


right coronary artery


Transient dilatation


  1. 1.

    Fasano MB (1995) Risks and benefits of intravenous immunoglobulin treatment in children. Curr Opin Pediatr 7:688–694

  2. 2.

    Hashino K, Ishii M, Iemura M, Akagi T, Kato H (2001) Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43:211–217

  3. 3.

    Jibiki T, Terai M, Kurosaki T, Nakajima H, Suzuki K, Inomata H, Terashima I, Honda T, Yasukawa K, Hamada H, Kohno Y (2004) Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr 163:229–233

  4. 4.

    Lang B, Duffy CM (2002) Controversies in the management of Kawasaki disease. Best Pract Res Clin Rheumatol 16:427–442

  5. 5.

    Lee MS, An SY, Jang GC and Kim DS (2002) A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate. Yonsei Med J 43:527–532

  6. 6.

    Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H (2004) Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 89:776–780

  7. 7.

    Mori M, Tomono N, Yokota S (1995) Coronary arteritis of Kawasaki disease unresponsive to high-dose intravenous gammaglobulin successfully treated with plasmapheresis. Nihon Rinsho Meneki Gakkai Kaishi 18:282–288

  8. 8.

    Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639

  9. 9.

    Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS and Flynn I (2003) Intravenous immunoglobulin for the treatment of Kawasaki disease in children (Cochrane Review). Cochrane Database Syst Rev 4: CD004000 (DOI 10.1002/14651858.CD004000)

  10. 10.

    Onouchi Z, Kawasaki T (1999) Overview of pharmacological treatment of Kawasaki disease. Drugs 58:813–822

  11. 11.

    Redwan EL (2002) Biochemical and immunological properties of four intravenous Immunoglobulin G preparations. Hum Antibodies 11:79–84

  12. 12.

    Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, Iemura M, Ishii M, Kato H (1999) Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatr Int 41:1–7

  13. 13.

    Shulman ST, Rowley AH (2004) Advances in Kawasaki disease. Eur J Pediatr 163:285–291

  14. 14.

    Suto F, Sakata K, Kamiya Y, Hamaoka K, Onouchi Z, Tanaka T, Nukina S (1998) Additional gamma-globulin therapy (IVGG) for the patients of Kawasaki disease who are resistant to first IVGG. Prog Med 18:1649–1651

  15. 15.

    Suto F, Sato H, Yoiyama K, Ozawa S, Teramachi S, Nakagawa Y, Kido S, Sakata K, Kamiya Y, Itoi T, Hamaoka K, Onouchi Z (1997) Predictors of coronary artery lesions after intravenous gamma-globulin therapy in Kawasaki disease. Prog Med 17:1820-1827

Download references

Author information

Correspondence to Koichi Sakata.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sakata, K., Hamaoka, K., Ozawa, S. et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr 166, 565–571 (2007).

Download citation


  • Cost
  • Discriminate analysis
  • Kawasaki disease
  • Immune globulin
  • Resistance